Genome & Company
Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea, Asia, Europe, South America, North America, and internationally. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities. The c… Read more
Genome & Company (314130) - Net Assets
Latest net assets as of September 2025: ₩95.37 Billion KRW
Based on the latest financial reports, Genome & Company (314130) has net assets worth ₩95.37 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩136.75 Billion) and total liabilities (₩41.38 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩95.37 Billion |
| % of Total Assets | 69.74% |
| Annual Growth Rate | -24.75% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 8.91 |
Genome & Company - Net Assets Trend (2021–2024)
This chart illustrates how Genome & Company's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Genome & Company (2021–2024)
The table below shows the annual net assets of Genome & Company from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩48.31 Billion | -22.61% |
| 2023-12-31 | ₩62.43 Billion | -35.84% |
| 2022-12-31 | ₩97.30 Billion | -14.20% |
| 2021-12-31 | ₩113.40 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Genome & Company's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11941643209000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩15.53 Billion | 32.14% |
| Other Components | ₩337.56 Billion | 698.71% |
| Total Equity | ₩48.31 Billion | 100.00% |
Genome & Company Competitors by Market Cap
The table below lists competitors of Genome & Company ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Karyopharm Therapeutics Inc
NASDAQ:KPTI
|
$126.81 Million |
|
Acres Commercial Realty Corp
NYSE:ACR
|
$126.82 Million |
|
Prime Mining Corp
OTCQX:PRMNF
|
$126.84 Million |
|
Priner Serviços Industriais S.A
SA:PRNR3
|
$126.86 Million |
|
1Stdibs.Com Inc
NASDAQ:DIBS
|
$126.75 Million |
|
SIMILARWEB LTD IS-01
F:63X
|
$126.74 Million |
|
Garofalo Health Care S.p.A
F:GHC
|
$126.70 Million |
|
Guangdong Jushen Logistics Co Ltd
SHE:001202
|
$126.68 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genome & Company's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 62,428,094,820 to 48,311,274,290, a change of -14,116,820,530 (-22.6%).
- Net loss of 20,112,455,750 reduced equity.
- Share repurchases of 33,837,560 reduced equity.
- New share issuances of 33,837,560 increased equity.
- Other factors increased equity by 5,995,635,220.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-20.11 Billion | -41.63% |
| Share Repurchases | ₩33.84 Million | -0.07% |
| Share Issuances | ₩33.84 Million | +0.07% |
| Other Changes | ₩6.00 Billion | +12.41% |
| Total Change | ₩- | -22.61% |
Book Value vs Market Value Analysis
This analysis compares Genome & Company's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.53x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.61x to 5.53x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | ₩3296.30 | ₩8610.00 | x |
| 2022-12-31 | ₩3452.29 | ₩8610.00 | x |
| 2023-12-31 | ₩2119.78 | ₩8610.00 | x |
| 2024-12-31 | ₩1555.70 | ₩8610.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genome & Company utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -41.63%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -72.49%
- • Asset Turnover: 0.19x
- • Equity Multiplier: 3.05x
- Recent ROE (-41.63%) is above the historical average (-51.93%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -36.79% | -7560.62% | 0.00x | 1.48x | ₩-43.39 Billion |
| 2022 | -53.28% | -368.05% | 0.08x | 1.78x | ₩-61.57 Billion |
| 2023 | -76.03% | -332.02% | 0.09x | 2.60x | ₩-53.71 Billion |
| 2024 | -41.63% | -72.49% | 0.19x | 3.05x | ₩-24.94 Billion |
Industry Comparison
This section compares Genome & Company's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genome & Company (314130) | ₩95.37 Billion | -36.79% | 0.43x | $126.77 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |